Skip to main content
Premium Trial:

Request an Annual Quote

DiaTech Licenses Vanderbilt's Personalized Tumor Test

NEW YORK (GenomeWeb News) – DiaTech Oncology has struck a license agreement with Vanderbilt University for a microkinetic assay that can be used to determine a patient's chemotherapy treatment and dosing needs, the university said today.

The Brentwood, Tenn.-based company has licensed the MiCK test, which was developed at the Vanderbilt University School of Medicine, which will be used in a service that measures the response through apoptosis of patients' cancer cells to a number of different chemotherapeutic drugs.

A lab analysis of the cancer cells is conducted in order to monitor and then compute the amounts of apoptosis caused by each of the drugs. DiaTech plans to provide oncologists with a drug-sensitivity profile for the patient within 24 to 48 hours.

Financial terms of the agreement were not released.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.